Eli Lilly is a big company that makes medicine. They have a new medicine called Zepbound that helps people lose weight. This medicine is becoming more popular than another similar medicine made by Novo Nordisk. Many people in the world are overweight or obese, so there is a lot of money to be made from these medicines. Eli Lilly is also making other good medicines for cancer and other diseases. That's why their company is doing very well. Read from source...

1. The title is misleading and sensationalized. It implies that Eli Lilly is winning the war on weight loss drugs, which is not a fact but an opinion based on one week's data of Zepbound overtaking Wegovy in prescriptions. A more accurate title would be "Zepbound Overtakes Wegovy In US Prescriptions: Is Eli Lilly Gaining An Edge In The Weight Loss Drug Market?"
2. The article relies heavily on sales figures and market projections to support its claims, but does not provide any evidence of the effectiveness or safety of the drugs. It also ignores other factors that may influence the prescription trends, such as price, availability, patient preference, doctor recommendation, side effects, etc.
3. The article compares Zepbound and Wegovy only, without mentioning other competitors in the weight loss drug market, such as Ozempic, Saxenda, Plenity, etc. It also does not consider the potential entry of generic versions or biosimilars that may affect the competition and pricing dynamics.
4. The article mentions Verzenio's sales growth as a positive indicator for Eli Lilly, but does not explain how it is related to the weight loss drug market or its future prospects. It also does not provide any context or comparison with other cancer drugs or treatments.
5. The article cites statistics from the International Diabetes Federation and the World Obesity Federation to highlight the growing demand for diabetes and weight-loss treatments, but does not specify the source, methodology, or accuracy of these data. It also does not address the ethical, social, or environmental implications of promoting and consuming such drugs.